Home2018-07-27T04:33:28+00:00

Novel cancer therapies targeting key cancer pathways

READ MORE
Prescient Therapeutics PTX

We are a clinical stage oncology company developing novel drugs
that show great promise as potential new therapies to treat a range of cancers.

prescient therapeutics

OUR COMPANY

Prescient Therapeutics’ novel compounds inhibit key tumor survival pathways, inhibiting cancer growth and overcoming resistance to prior therapies.

Digital Brochure

Two Page Fact Sheet

prescient therapeutics

OUR SCIENCE

Our technologies emanate from renowned institutions Yale University and the Moffitt Cancer Center and are backed by a myriad of peer review publications.

prescient therapeutics

LATEST NEWS

31/07/2018June 2018 Appendix 4C - QuarterlyPDF
26/07/2018US Patent Granted for PTX-200 for Ovarian Cancer TreatmentPDF
03/07/2018PTXO Options UpdatePDF
31/05/2018Letter to PTXO Option HoldersPDF
01/05/2018CSO Precision Medicine PresentationPDF
24/04/2018Prof. Said Sebti Interview - New cancer therapy shows promising resultsLink